[go: up one dir, main page]

CH603545A5 - - Google Patents

Info

Publication number
CH603545A5
CH603545A5 CH568673A CH568673A CH603545A5 CH 603545 A5 CH603545 A5 CH 603545A5 CH 568673 A CH568673 A CH 568673A CH 568673 A CH568673 A CH 568673A CH 603545 A5 CH603545 A5 CH 603545A5
Authority
CH
Switzerland
Application number
CH568673A
Inventor
Arthur Dr Rer Nat Scherm
Dezsoe Dr Peteri
Original Assignee
Merz & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2219256A external-priority patent/DE2219256C3/de
Priority claimed from DE2318461A external-priority patent/DE2318461A1/de
Application filed by Merz & Co filed Critical Merz & Co
Publication of CH603545A5 publication Critical patent/CH603545A5/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CH568673A 1972-04-20 1973-04-19 CH603545A5 (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2219256A DE2219256C3 (de) 1972-04-20 1972-04-20 Oral und parenteral verabreichbares Arzneimittel zur Behandlung der Parkinson'sehen Krankheit
DE2318461A DE2318461A1 (de) 1973-04-12 1973-04-12 Verfahren zur herstellung von 1,3,5trisubstituierten adamanta-verbindungen

Publications (1)

Publication Number Publication Date
CH603545A5 true CH603545A5 (is) 1978-08-31

Family

ID=25763107

Family Applications (1)

Application Number Title Priority Date Filing Date
CH568673A CH603545A5 (is) 1972-04-20 1973-04-19

Country Status (8)

Country Link
US (1) US4122193A (is)
JP (1) JPS4918860A (is)
CA (1) CA974518A (is)
CH (1) CH603545A5 (is)
ES (1) ES413944A1 (is)
FR (1) FR2182998B1 (is)
GB (1) GB1393503A (is)
NL (1) NL7305644A (is)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
WO1992017168A1 (en) * 1991-04-04 1992-10-15 The Children's Medical Center Corporation Method of preventing nmda receptor-mediated neuronal damage
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
DE4225730C2 (de) * 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
CA2457011C (en) * 2001-08-20 2012-04-24 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
EP1298581A1 (fr) * 2001-09-27 2003-04-02 C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa Procédé et dispositif pour calculer les valeurs des neurones d'un réseau neuronal
WO2004037234A2 (en) 2002-10-24 2004-05-06 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
RU2246482C2 (ru) * 2002-12-25 2005-02-20 ООО "Циклан" Способ получения гидрохлорида 1-амино-3,5-диметиладамантана
KR20070104480A (ko) * 2003-05-27 2007-10-25 포레스트 래보러토리즈, 인코포레이티드 우울증 및 그 밖의 기분장애의 치료를 위한 nmda수용체 길항제 및 선택적 세로토닌 재흡수 억제제의 배합물
CN1240668C (zh) * 2003-09-10 2006-02-08 上海医药工业研究院 一种新的盐酸美金刚制备方法
JP2007509165A (ja) * 2003-10-22 2007-04-12 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン アミロイドパシーにおいて、フィブリロジェニックAβペプチドの沈着を改変するために、1−アミノシクロヘキサン誘導体を使用する方法
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
WO2005069742A2 (en) * 2003-12-10 2005-08-04 Sun Pharmaceutical Industries Limited Crystal form ii of memantine hydrochloride
DK1703902T3 (da) * 2004-01-05 2011-02-14 Merz Pharma Gmbh & Co Kgaa Memantin til behandling af mild til moderat Alzheimer's sygdom
CN100363329C (zh) * 2004-01-09 2008-01-23 南京大学 合成美金刚胺盐酸盐的方法
US7456224B2 (en) * 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
WO2006009769A1 (en) * 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
EP2397122B1 (en) 2004-06-17 2014-05-14 Merz Pharma GmbH & Co. KGaA Formulations of neramexane dosage forms
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
KR20070046185A (ko) * 2004-09-23 2007-05-02 메르츠 파마 게엠베하 운트 코. 카가아 소아 행동장애의 치료를 위한 메만틴
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
HRP20090676T1 (hr) * 2005-01-11 2010-01-31 Teva Pharmaceutical Fine Chemicals S.R.L. Postupak dobivanja 1-amino-3,5-dimetiladamantan-hidroklorida
ITMI20050833A1 (it) 2005-05-10 2006-11-11 A M S A S P A Anonima Materie Sintetiche Affini Nuovo procedimento per la sintesi di aminoadamantani
EA013474B1 (ru) * 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
WO2007016155A2 (en) 2005-07-27 2007-02-08 Dov Pharmaceutical, Inc. Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
ES2379181T3 (es) * 2006-02-21 2012-04-23 Hexal Ag Procedimiento para la preparación de adamantanaminas
US20080033054A1 (en) * 2006-03-27 2008-02-07 Valeriano Merli Process for preparing memantine hydrochloride substantially free of impurities
AR063680A1 (es) 2006-08-04 2009-02-11 Merz Pharma Gmbh & Co Kgaa Derivados de pirazolo[1, 5-a]pirimidina, metodos e intermediario para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion de mglur5.
EP1908748A1 (en) * 2006-10-05 2008-04-09 Krka Process for the preparation of memantine and its hydrochloric acid salt form
US20080108643A1 (en) * 2006-11-03 2008-05-08 Forest Laboratories Holdings Limited Method for treating autism
WO2008077092A2 (en) 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Combined effects of topiramate and ondansetron on alcohol consumption
JP5313125B2 (ja) 2007-02-28 2013-10-09 旭化成ファーマ株式会社 スルホンアミド誘導体
US20090069374A1 (en) 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0713930D0 (en) 2007-07-18 2007-08-29 Generics Uk Ltd Novel assay methods
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EP2111858A1 (en) 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Novel treatment for alzheimer's disease
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
EP2138173A1 (en) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
JP5195256B2 (ja) * 2008-10-10 2013-05-08 東ソー株式会社 アミノアダマンタン誘導体の製造方法
HRP20090186A2 (hr) 2009-03-31 2010-10-31 Institut Ruđer Bošković Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona
WO2010112221A1 (en) 2009-04-03 2010-10-07 Synthon B.V. Pharmaceutical compositions comprising memantine
CN102070463A (zh) * 2009-06-11 2011-05-25 辽宁利锋科技开发有限公司 具有金刚烷结构药物美金刚胺及其衍生物和类似物抗肿瘤新适应症的应用
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
US20110251239A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
AR083475A1 (es) 2010-10-18 2013-02-27 Merz Pharma Gmbh & Co Kgaa Moduladores de receptores de glutamato metabotropicos
CA2814905A1 (en) 2010-10-29 2012-05-03 Merz Pharma Gmbh & Co. Kgaa Indole derivatives and process for their preparation
WO2012068161A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
AR084515A1 (es) 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
WO2012085166A1 (en) 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
WO2012152854A1 (en) 2011-05-12 2012-11-15 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
WO2012172093A1 (en) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
CN103288650B (zh) * 2012-02-28 2015-09-30 广州白云山制药股份有限公司广州白云山制药总厂 一种盐酸1-氨基-3,5-二甲基金刚烷的制备方法
EP2650284A1 (en) 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Heterocyclic derivatives as metabotropic glutamate receptor modulators
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods
MX381561B (es) 2013-12-20 2025-03-12 Agenebio Inc Derivados de benzodiazepina, composiciones, y métodos para tratar el deterioro cognitivo.
CA2938671A1 (en) 2014-02-04 2015-08-13 Forest Laboratories Holdings Limited Donepezil compositions and method of treating alzheimer's disease
CN113264939A (zh) 2015-06-19 2021-08-17 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
JP6354701B2 (ja) * 2015-08-19 2018-07-11 大日本印刷株式会社 高純度メマンチン塩酸塩の製造法
US10835499B2 (en) 2015-12-30 2020-11-17 Corium, Inc. Systems and methods for long term transdermal administration
US11541018B2 (en) 2016-06-23 2023-01-03 Corium, Llc Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
AU2017302305A1 (en) 2016-07-27 2019-02-14 Corium, LLC. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
KR20230109782A (ko) 2016-07-27 2023-07-20 코리움, 엘엘씨 아민 약물의 나트륨 바이카보네이트 제자리 전환 구동된경피성 전달
CA3032103A1 (en) 2016-07-27 2018-02-01 Corium International, Inc. Memantine transdermal delivery systems
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio, Inc. derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10369187B2 (en) 2017-02-09 2019-08-06 Vanderbilt University Peptide regulators of JNK family kinases
JP2019094304A (ja) * 2017-11-27 2019-06-20 学校法人順天堂 オートファジー誘導剤
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
EA202190076A1 (ru) 2018-06-19 2021-09-22 Эйджинбайо, Инк. Производные бензодиазепина, композиции и способы лечения когнитивных нарушений
EP3721857A1 (en) * 2019-04-11 2020-10-14 Dentsply DeTrey GmbH Dental composition
WO2021232232A1 (zh) * 2020-05-19 2021-11-25 山东泓瑞医药科技股份公司 一种金刚烷胺的制备方法
IL319072A (en) 2022-08-19 2025-04-01 Agenebio Inc History of Benzazepine, Compositions and Methods for Treating Cognitive Impairment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH76A (fr) * 1888-11-14 1889-01-09 Carnal Paul E Nouveau système de boîte de montre pouvant servir à volonté comme savonnette ou comme boîte à glace
US3391142A (en) * 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
FR1545327A (fr) * 1966-11-25 1968-11-08 Boehringer Sohn Ingelheim Nouveau procédé de fabrication de 2-hydroxy-3-aryloxy-propylamines secondaires
US3450761A (en) * 1967-03-30 1969-06-17 Sun Oil Co 1-aminoethyldimethyladamantane
US3929888A (en) * 1968-08-27 1975-12-30 Lilly Industries Ltd 2-Phenyl-adamantanealkylamine compounds and their salts
US3789073A (en) * 1970-04-22 1974-01-29 Squibb & Sons Inc Adamantylalkylaminoalkyl benzamides

Also Published As

Publication number Publication date
JPS4918860A (is) 1974-02-19
NL7305644A (is) 1973-10-23
GB1393503A (en) 1975-05-07
FR2182998B1 (is) 1976-12-31
CA974518A (en) 1975-09-16
US4122193A (en) 1978-10-24
FR2182998A1 (is) 1973-12-14
ES413944A1 (es) 1976-06-01

Similar Documents

Publication Publication Date Title
FR2182998B1 (is)
FR2176724B1 (is)
CS162796B2 (is)
JPS4963232A (is)
FR2189424A1 (is)
JPS48102013A (is)
JPS4936180A (is)
JPS4878943A (is)
CS168677B2 (is)
JPS5115017B2 (is)
FR2187581A1 (is)
FR2204296A5 (is)
JPS4935982A (is)
JPS5222652Y2 (is)
JPS5219848Y2 (is)
JPS4814755Y1 (is)
CS167536B1 (is)
CS169746B1 (is)
JPS4993926U (is)
CS159023B1 (is)
CS159548B1 (is)
CS159966B1 (is)
CS163448B1 (is)
CS165031B1 (is)
CS165489B1 (is)

Legal Events

Date Code Title Description
PL Patent ceased
PL Patent ceased